Men diagnosed at this hospital trust can access the following services:

• Diagnostic Facilities:
• Multiparametric MRI
• Transperineal biopsy under local anaesthetic
• Transperineal biopsy under general anaesthetic
• Choline PET
• PSMA (prostate-specific membrane antigen) PET scan
• Whole body MRI
• Isotope bone scan

• Treatment Facilities:
• External beam radiotherapy (EBRT)
• Stereotactic body radiation therapy (SBRT)
• Chemotherapy
• Joint specialist MDT clinic

• Support Service Facilities:
• Prostate cancer-specific CNSs
• Advanced PCa CNS
• Urology CNS
• Specialist continence services
• Psychological counselling

For Wales, this data completeness relates to patients diagnosed between April 2022 and March 2023.
For England, this data completeness relates to patients diagnosed in 2021. This is the data completeness of the National Cancer Registration Dataset (NCRD). For data completeness of the Rapid Cancer Registration Dataset (RCRD), please refer to the NPCA quarterly reports.

	Diagnosing Trust	Specialist MDT
No. of Cancer Registry records	219	1265
Performance Status recorded	79%	69%
PSA completed	85%	45%
Gleason Score completed	77%	82%
TNM completed	77%	61%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men with disease status determined	991	39897
Percentage of men diagnosed with metastatic disease	10%	17%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men diagnosed with low-risk localised disease	82	4684
Percentage of men with low-risk localised disease receiving radical treatment	11%	8%
No. of men diagnosed with locally advanced disease	388	15410
Percentage of men diagnosed with locally advanced disease receiving radical treatment	73%	68%